poisar

Stocks · News reference

Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VCYT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

    AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%.

    ANGOGMEDVCYTWST
  2. Na

    Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

    Veeva Systems (VEEV) delivered strong Q2 fiscal 2027 results, beating estimates and raising its full-year outlook, driven by expanding Vault CRM adoption with 12 of top 20 biopharmas committed and over 180 customers live. The company is advancing AI initiatives with Veeva Falcon attracting early adopters. However, market saturation in the life sciences CRM space and intensifying competition from traditional and AI-powered platforms could constrain future growth rates.

    VEEVGMEDVCYTWST
  3. Na

    Is it the Right Time to Add Phibro Stock to Your Portfolio?

    Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.

    PAHCZTSVCYTABTGMED